MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
65.18
+0.52
+0.80%
After Hours: 63.92 -1.26 -1.93% 16:39 05/14 EDT
OPEN
64.80
PREV CLOSE
64.66
HIGH
65.61
LOW
63.43
VOLUME
572.88K
TURNOVER
--
52 WEEK HIGH
85.25
52 WEEK LOW
38.51
MARKET CAP
2.80B
P/E (TTM)
-57.4982
1D
5D
1M
3M
1Y
5Y
1D
TARSUS AND JOHN CENA PARTNER TO RAISE AWARENESS OF DEMODEX BLEPHARITIS, A COMMON EYELID DISEASE AFFECTING APPROXIMATELY 25 MILLION AMERICANS
Reuters · 8h ago
Weekly Report: what happened at TARS last week (0504-0508)?
Weekly Report · 3d ago
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Pipeline Growth Expectations
Simply Wall St · 4d ago
Mizuho Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)
TipRanks · 6d ago
Tarsus Pharmaceuticals (TARS) Gets a Buy from Guggenheim
TipRanks · 6d ago
Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives
Simply Wall St · 6d ago
Tarsus Pharmaceuticals to present at Bank of America Securities health care conference
PUBT · 6d ago
Tarsus to Participate in Upcoming Investor Conferences
Barchart · 05/07 16:00
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.